These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 15446566)

  • 1. [A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan].
    Hada M; Mizutari K
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1407-10. PubMed ID: 15446566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
    Villalona-Calero M; Schaaf L; Phillips G; Otterson G; Panico K; Duan W; Kleiber B; Shah M; Young D; Wu WH; Kuhn J
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):23-33. PubMed ID: 16685529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A case of advanced pancreatic cancer with remarkable response to thalidomide, celecoxib and gemcitabine].
    Hada M; Mizutari K
    Gan To Kagaku Ryoho; 2004 Jun; 31(6):959-61. PubMed ID: 15222121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
    Lipton A; Campbell-Baird C; Witters L; Harvey H; Ali S
    J Clin Gastroenterol; 2010 Apr; 44(4):286-8. PubMed ID: 20216081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.
    Lipton A; Harvey H; Witters L; Kerr S; Legore K; Campbell C
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):43-5. PubMed ID: 15685834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.
    Natale RB
    Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):22-6. PubMed ID: 12886870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Report of two cases with pleural effusion and ascites that responded dramatically to the combination of thalidomide, celecoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities].
    Hada M
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):613-7. PubMed ID: 15114711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.
    Trifan OC; Durham WF; Salazar VS; Horton J; Levine BD; Zweifel BS; Davis TW; Masferrer JL
    Cancer Res; 2002 Oct; 62(20):5778-84. PubMed ID: 12384538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
    Csiki I; Morrow JD; Sandler A; Shyr Y; Oates J; Williams MK; Dang T; Carbone DP; Johnson DH
    Clin Cancer Res; 2005 Sep; 11(18):6634-40. PubMed ID: 16166442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer.
    Crane CH; Mason K; Janjan NA; Milas L
    Am J Clin Oncol; 2003 Aug; 26(4):S81-4. PubMed ID: 12902862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine].
    Hada M; Horiuchi T; Shinji H
    Gan To Kagaku Ryoho; 2006 Feb; 33(2):259-61. PubMed ID: 16484869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
    El-Rayes BF; Zalupski MM; Manza SG; Rusin B; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Shields AF; Philip PA
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):283-9. PubMed ID: 17429629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.
    Milas L; Mason KA; Crane CH; Liao Z; Masferrer J
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):15-24. PubMed ID: 12800601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.
    El-Rayes BF; Ali S; Sarkar FH; Philip PA
    Mol Cancer Ther; 2004 Nov; 3(11):1421-6. PubMed ID: 15542781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
    Prince HM; Mileshkin L; Roberts A; Ganju V; Underhill C; Catalano J; Bell R; Seymour JF; Westerman D; Simmons PJ; Lillie K; Milner AD; Iulio JD; Zeldis JB; Ramsay R
    Clin Cancer Res; 2005 Aug; 11(15):5504-14. PubMed ID: 16061867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine, irinotecan and celecoxib in patients with biliary cancer.
    Watkins JF; Mayo MS; Smith HJ; Williamson SK
    Anticancer Drugs; 2009 Apr; 20(4):294-300. PubMed ID: 19177022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP].
    Hada M; Kazuhiro M
    Gan To Kagaku Ryoho; 2004 Dec; 31(13):2191-4. PubMed ID: 15628770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
    Pan CX; Loehrer P; Seitz D; Helft P; Juliar B; Ansari R; Pletcher W; Vinson J; Cheng L; Sweeney C
    Oncology; 2005; 69(1):63-70. PubMed ID: 16088234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
    Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
    Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
    Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.